Treatments for Autoimmune Diseases

arGentis™ Pharmaceuticals, LLS is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU.


The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc.


Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Scleroderma
Scleroderma is a chronic autoimmune disease in which the skin and connective tissue tightens and hardens. Median survival from diagnosis is approximately 11 years. Patients experience a deteriorating quality of life and typically die from complications of the disease.   There is no cure or effective treatment for the disease. 

Genotype Marker​

Rheumatoid Arthritis

Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of your joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.


Biomarkers enable physicians to choose treatments that will work in a specific patient.  In addition there is a quest to use biomarkers to identify patients who will have an adverse reaction to a treatment.  This is often referred to as “personalized medicine.”  

Autoimmune Diseases

Aut​oImmune Disease Treatments

arGentis
Pharmaceuticals, LLC